IOFLUPANE I-123 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ioflupane I-123, and when can generic versions of Ioflupane I-123 launch?
Ioflupane I-123 is a drug marketed by Curium and is included in one NDA.
The generic ingredient in IOFLUPANE I-123 is ioflupane i-123. Two suppliers are listed for this compound. Additional details are available on the ioflupane i-123 profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ioflupane I-123
A generic version of IOFLUPANE I-123 was approved as ioflupane i-123 by CURIUM on March 30th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IOFLUPANE I-123?
- What are the global sales for IOFLUPANE I-123?
- What is Average Wholesale Price for IOFLUPANE I-123?
Summary for IOFLUPANE I-123
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Clinical Trials: | 8 |
| Patent Applications: | 102 |
| DailyMed Link: | IOFLUPANE I-123 at DailyMed |
Recent Clinical Trials for IOFLUPANE I-123
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GE Healthcare | Phase 1 |
| PPD | Phase 1 |
| GE Healthcare | Phase 3 |
Pharmacology for IOFLUPANE I-123
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Radiopharmaceutical Activity |
US Patents and Regulatory Information for IOFLUPANE I-123
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curium | IOFLUPANE I-123 | ioflupane i-123 | SOLUTION;INTRAVENOUS | 213792-001 | Mar 30, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
